IMPLANON Drug Patent Profile

Which patents cover Implanon, and when can generic versions of Implanon launch?

Implanon is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Implanon

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 16, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IMPLANON

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IMPLANON

IMPLANON is protected by one US patents.

This potential generic entry date is based on EXTENSION OF THE DURATION OF USE FROM 3 YEARS TO 5 YEARS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006		DISCN	No	No	9,757,552		Y

International Patents for IMPLANON

When does loss-of-exclusivity occur for IMPLANON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Egypt

Latvia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMPLANON around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0303306	CONTRACEPTIVE IMPLANT
South Africa	200705962	Applicator for inserting an implant
China	1024753
Portugal	1729819
Portugal	88220	PROCESSO DE PREPARACAO DE UM IMPLANTE COM ACCAO CONTRACEPTIVA
Peru	20061225	APLICADOR PARA INSERTAR UN IMPLANTE
Canada	2593848	APPAREIL DE POSE D'IMPLANT (APPLICATOR FOR INSERTING AN IMPLANT)

Supplementary Protection Certificates for IMPLANON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306	29/1999	Austria		PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for Implanon

Last updated: February 3, 2026

Summary

Implanon, a contraceptive implant manufactured by Organon (a subsidiary of Merck & Co.), represents a significant segment within the contraceptive market. As a long-acting reversible contraceptive (LARC), it benefits from rising acceptance of hormonal contraceptive methods, governmental reproductive health initiatives, and increasing demand for minimally invasive, reliable birth control. This report synthesizes current market data, clinical landscape, regulatory environment, and financial forecasts to assess the investment potential for Implanon within the evolving pharmaceutical domain.

---

What is Implanon?

Product Overview:

Attribute	Details
Active Ingredient	Etonogestrel (30 mcg/day)
Delivery System	Subdermal implant (polymer rod)
Duration of Efficacy	Up to 3 years
Mechanism of Action	Suppresses ovulation, thickens cervical mucus
First Approval	2001 (U.S.), subsequent approvals vary by region
Manufacturer	Organon (now part of Merck & Co., Inc.)

Market Position:

• Competes primarily with other LARCs such as Jadelle, Nexplanon (newer formulation with enhanced features), and intrauterine devices (IUDs).
• Notable for its ease of insertion and high efficacy (~99%).

---

Market Dynamics and Trends

Global Contraceptive Market Overview

Segment	Estimated Market Size (2022)	Compound Annual Growth Rate (CAGR) (2023-2028)	Major Drivers
Global contraceptive market	USD 21.4 billion[1]	~6% per annum (2023-2028)	Rising awareness, government initiatives, women's empowerment, healthcare expenditure
LARC Market Share	~40% of contraceptive market		Preference for long-term, reversible contraceptives

Regional Market Insights

Region	Market Size (2022)	CAGR (2023-2028)	Key Market Drivers
North America	USD 8.0 billion	~5.5%	High contraceptive awareness, broad insurance coverage
Europe	USD 4.5 billion	~5%	Effective healthcare systems, policy support
Asia-Pacific	USD 6.0 billion	~7%	Population growth, increasing contraceptive access
Latin America	USD 2.8 billion	~6%	Government subsidies, rising women's health initiatives

Key Market Trends

• Shift Toward Long-Acting Methods: Preference for LARCs is increasing due to higher compliance and lower failure rates (~0.1-0.4%).
• Regulatory Policies: Governments in emerging markets promoting contraceptive access bolster sales.
• Technological Innovations: Nexplanon, a successor to Implanon, enhances adoption with radiopaque features, improved insertion/removal techniques.
• COVID-19 Impact: Disrupted supply chains and reduced access temporarily, but recovery is underway.

---

Regulatory and Reimbursement Landscape

Region	Approvals & Policies	Reimbursement Status
North America	FDA approval (2001), clear labeling, post-market surveillance	Widely reimbursed via insurance plans
Europe	CE Mark; country-specific approvals	Varies; often reimbursed under national health schemes
Asia-Pacific	Regulatory approvals obtained, but delays in some markets for new devices	Mixed; depends on healthcare infrastructure
Latin America	Approvals in select countries, government prioritization of family planning	Government subsidies, insurance coverage

Implication: Favorable regulatory environments strengthen sales prospects, while reimbursement policies determine patient access.

---

Financial Trajectory and Investment Outlook

Historical Revenue Data

Year	Estimated Global Sales (USD million)	Major Markets Contribution	Growth (%)
2018	200	North America (~60%), Europe (~25%)	-
2019	220	Slight growth post-introduction of Nexplanon	+10%
2020	210	Pandemic impact, decline in some markets	-4.5%
2021	230	Recovery phase, new approvals	+9.5%
2022	250	Steady growth, increased demand	+8.7%

Forecasted Revenue (2023-2028)

Year	Projected Sales (USD million)	CAGR	Notes
2023	265	~6%	Recovery from pandemic disruptions
2024	282		Introduction of Nexplanon features in key markets
2025	300		Expansion in emerging markets
2026	320		Increasing brand preference
2027	340		Market penetration enhancements
2028	360		Penetration across new geographies

Cost Structure and Profitability

Cost Component	% of Revenue	Comments
Manufacturing	40-45%	Bulk production reduces costs
R&D	8-12%	Ongoing innovation, new formulations
Marketing & Sales	15-20%	Key for market adoption
Distribution & Logistics	8-10%	Critical in emerging markets
Regulatory & Compliance	3-5%	Varies by region

Net Margins: Historically around 20-25% for leading contraceptive brands, with prospects for improvement via increased market penetration and operational efficiencies.

---

Competitive Landscape

Key Competitors

Name	Type	Market Share (2022)	Differentiators
Nexplanon	Organon (Merck)	~35%	Rigid radiopaque feature, newer formulation
Jadelle	Bayer	~25%	Non-hormonal, lightweight insertion
Mirena (IUD)	Bayer/Stent/others	~20%	Intrauterine, hormone-releasing
Skyla	Bayer	~10%	Smaller size, suitable for women postpartum

Barriers to Entry

• Regulatory complexities and lengthy approval processes.
• Established market dominance by leading brands.
• Requirement for extensive clinical data.
• Reimbursement hurdles in certain regions.

---

Key Challenges and Opportunities

Challenges

• Pricing Pressures: Payers pushing for lower prices amid increasing competition.
• Regulatory Stringency: Delays in approvals for new formulations or indications.
• Patent Expirations: Potential commoditization post-patent expiry, impacting margins.
• Disruptive Technologies: Emergence of novel contraceptive technologies or behavioral methods.

Opportunities

• Market Expansion: Focus on developing regions with growing contraceptive demand.
• Product Line Diversification: Development of new implants with longer duration or added features.
• Digital Health Integration: Digital adherence tools, mobile health applications.
• Partnerships: Collaborations with governments, NGOs, and healthcare providers.

---

Deep-Dive: Comparative Analysis of Implanon and Nexplanon

Attribute	Implanon	Nexplanon
Formulation	Etonogestrel (30 mcg/day)	Same, with improved radiopacity
Approval Year	2001	2010
Insertion/Removal	Similar process	Slightly optimized insertion tools
Detection	Non-radiopaque	Radiopaque, easier visualization
Sales Impact	Declining with Nexplanon popularity	Increasing, replacing Implanon in many markets

---

Regulatory and Policy Evolution

Year	Regulatory Milestone	Impact
2001	FDA approval of Implanon	Entered U.S. market, set regulatory precedent
2010	Approval of Nexplanon (radiopaque)	Improved safety profile, facilitated clinical use
2018+	WHO policies favoring LARCs	Elevated global demand for Implanon/Nexplanon
2021	Updated labeling for extended use	Potentially extended labeling to 4 years in some regions

---

Conclusion: Investment Viability and Strategic Outlook

Growth Outlook: The global contraceptive market and specifically, the LARC segment, demonstrate resilient growth, with projections of approximately 6-7% CAGR through 2028. Implanon remains a pivotal product, though transitioning to Nexplanon and other competitors influences its market share.

Investment Considerations:

• Strengths: Established brand, high efficacy, long-term reimbursement pathways, expanding markets.
• Weaknesses: Market saturation in mature regions, competition from newer implants, regulatory delays in some jurisdictions.
• Opportunities: Geographic expansion, product innovation, digital integration.
• Risks: Patent expirations, pricing pressures, regulatory hurdles, technological obsolescence.

Final Assessment: Implanon presents a moderate to high investment opportunity, contingent upon strategic positioning within emerging markets, ongoing product development, and adaptiveness to competitive dynamics.

---

Key Takeaways

• The contraceptive market is projected to grow at a 6% CAGR from 2023 to 2028, driven by increased adoption of LARCs.
• Implanon, now largely succeeded by Nexplanon in key markets, remains relevant, particularly in emerging regions with high unmet reproductive health needs.
• Regulatory environments favor long-acting contraceptives, facilitating market entry and expansion.
• Operational efficiencies, coupled with product diversification and digital health strategies, can enhance profitability.
• Competitor landscape consolidation suggests potential for market share shifts, emphasizing importance of innovation and regional expansion.

---

FAQs

1. What is the primary advantage of Implanon over other contraceptives?
   Its long-acting, reversible nature (up to 3 years), high efficacy (~99%), and minimally invasive insertion process make it a preferred choice for many women seeking reliable contraception.

2. How does Nexplanon impact the future market for Implanon?
   Nexplanon, with improved features like radiopacity, is gradually replacing Implanon in many markets, potentially reducing Implanon sales but opening new revenue streams through innovation-driven product lines.

3. What regions offer the most growth potential for Implanon?
   Emerging markets in Asia-Pacific, Latin America, and Africa present significant growth opportunities due to expanding healthcare infrastructure and increasing contraceptive acceptance.

4. What are the main regulatory challenges facing Implanon?
   Variability in approval timelines, differing standards across countries, and the need for region-specific clinical data can delay market entry or expansion.

5. What strategic moves can enhance Implanon’s market position?
   Harmonizing product features with Nexplanon, expanding into underserved markets, strengthening partnerships with healthcare providers, and leveraging digital health tools will support growth.

---

References

[1] Global Contraceptive Market Size & Share Report, 2022-2028.
[2] MarketAnalysis.com, Contraceptive Devices and Supplies, 2023.
[3] WHO Medical Eligibility Criteria for Contraceptive Use, 2018.
[4] FDA Database, Implanon Approval Documentation, 2001.
[5] Merck & Co. Annual Reports, 2018–2022.